In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Millimed's Play in Interventional Neurology

Executive Summary

Ten years ago, a group of executives launched Jomed with the thought of challenging the large cardiovascular device companies as a global player. Jomed never quite achieved that goal--though it came close. Now, with an innovative NO-loaded balloon, some former Jomed executives hope to do in interventional neurology what they tried to do in interventional cardiology.

You may also be interested in...

Biotronik's Disappearing Act

Any concerns about coronary stents and their safety have, obviously, long been put to rest. But one concern still lingers in the minds of some: why use a permanent device to do a temporary job? Phrased differently, how much better would it be to have a stent that, upon completing the remodeling job to keep the arteries open, simply disappeared? That's the promise of bioabsorbable stents. And one company, Berlin-based Biotronik GMBH & Co., hopes to capitalize on that promise.

Millimed models Jomed in interventional neurology

Former Jomed CEO Tor Peters is back, trying to build another major device company, this time in interventional neurology and modeled after the strategy he used at Jomed.

Jomed's Global Positioning

Over the past several years, Swiss Jomed has been one of the few small European stent companies to grow into a major cardiovascular device company. Last year's successful IPO was testimony to the company's strong sales growth. But it was two deals the company did following soon after the IPO, the acquisitions of US-based MediDyne and EndoSonics, that will test whether Jomed is ready to break out of the pack and compete on a truly global scale with medical device giants such as Guidant and Medtronic.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts